Gastric mapping study for people on semaglutide
Part of Digestive system clinical trials.
This study uses a non-invasive test (body surface gastric mapping) to look at stomach activity in people taking semaglutide. It aims to understand how the medicine affects digestion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You should not have any ongoing stomach or gut symptoms (based on standard criteria).
- If you have diabetes, your blood sugar control must meet certain levels (HbA1c above 7%, fasting blood sugar below 15 mmol/L).
- You cannot be currently using Ozempic, similar GLP-1 medicines, or regular insulin (in the last 3 months).
- You cannot have a confirmed diagnosis of gastroparesis (delayed stomach emptying).
- You cannot be pregnant or breastfeeding, and you must have healthy skin on your upper belly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new stomach test (Body Surface Gastric Mapping) with a standard one (Gastric Emptying Scintigraphy) to see which helps doctors better manage gastroparesis. You may join if you have ongoing stomach symptoms like nausea or vomiting and have been referred for a stomach emptying test.
This study tests a stomach mapping device (BSGM) to see how a prokinetic medication changes stomach activity in people with gastroparesis or functional dyspepsia. If you qualify, you'll have two non-invasive recordings—one before and one during your treatment.
This study checks whether a noninvasive “mapping” test placed on the belly and chest can help tell apart people with certain upper stomach symptoms from healthy controls. It may help researchers better understand stomach function and symptoms without relying only on invasive tests.
This trial looks at how having neuropathy (nerve damage) might increase the risk of food staying too long in the stomach when taking semaglutide. It could help find out who needs extra monitoring.
This study uses MRI scans to look at how the diabetes medication semaglutide affects body composition in people with type 2 diabetes and obesity. It may help doctors understand how this treatment works in the body.
This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.
Hear when a new Gastroparesis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.